Live moderated video webcast roundtable with members of the iTolerance absorption squad to beryllium held connected Thursday, October 27th astatine 3:00 PM ET
MIAMI, FL / ACCESSWIRE / October 24, 2022 / iTolerance, Inc. ("iTolerance" oregon the "Company"), an early-stage regenerative medicine institution processing technologies to alteration tissue, organoid oregon compartment therapy without the request for life-long immunosuppression, contiguous announced that Dr. Anthony Japour, Chief Executive Officer of iTolerance on with different members of the iTolerance Management Team volition enactment successful the Virtual Investor Pioneering Regenerative Medicine Without Immunosuppression Roundtable Event connected Thursday, October 27, 2022 astatine 3:00 PM ET.
iTolerance, Inc., Wednesday, September 7, 2022, Press merchandise picture
As portion of the virtual roundtable event, the Company volition sermon its iTOL-100 level technology, a biotechnology-derived Strepavidin-FasL fusion protein, a synthetic signifier of the people occurring macromolecule FasL, mixed with a biotin-PEG microgel (SA-FasL microgel) that perchance allows for convenient and effectual co-administration with implanted cells oregon organoids to induce section immune tolerance without the request for life-long immunosuppression. In pre-clinical studies, iTolerance's level has been shown to found durable, localized immune tolerance, allowing the implanted tissue, organoid oregon compartment therapy to relation arsenic a replacement for damaged autochthonal cells.
In summation to the moderated information of the event, investors and funny parties volition person the accidental to taxable questions. The Company volition reply arsenic galore questions arsenic imaginable during the event.
A live video webcastof the Virtual Investor Pioneering Regenerative Medicine Without Immunosuppression Roundtable Event volition beryllium disposable connected the Events leafage connected the Company's website (itolerance.com). A webcast replay volition beryllium disposable 2 hours pursuing the unrecorded presumption and volition beryllium accessible for 90 days.
About iTolerance, Inc.
iTolerance is an early-stage privately held regenerative medicine institution processing technologies to alteration tissue, organoid oregon compartment therapy without the request for life-long immunosuppression. Leveraging its proprietary biotechnology-derived Strepavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) level technology, iTOL-100, iTolerance is advancing a pipeline of programs utilizing some allogenic pancreatic islets and stem cells that person the imaginable to cure diseases. The Company's pb program, iTOL-101 is being developed for Type 1 Diabetes and successful a pre-clinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited semipermanent relation with power of humor glucose levels and restoration of insulin secretion without the usage of chronic immune suppression. The Company's 2nd pb candidate, iTOL-102, is leveraging important advancements successful stem cells to deduce pancreatic islets which allows an inexhaustible proviso of insulin-producing cells. Utilizing iTOL-100 to induce section immune tolerance, iTOL-102 has the imaginable to beryllium a cure for Type 1 Diabetes without the request for life-long immunosuppression. Additionally, the Company is processing iTOL-201 for liver nonaccomplishment and iTOL-301 arsenic a imaginable regenerative macromolecule and compartment therapy that leverages stem compartment sources to nutrient proteins oregon hormones successful the assemblage successful conditions of precocious unmet request without the request for life-long immunosuppression. For much information, delight sojourn itolerance.com.
Forward-Looking Statements
This property merchandise contains "forward-looking statements" wrong the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. When utilized herein, words specified arsenic "anticipate", "being", "will", "plan", "may", "continue", and akin expressions are intended to place forward-looking statements. In addition, immoderate statements oregon accusation that notation to expectations, beliefs, plans, projections, objectives, show oregon different characterizations of aboriginal events oregon circumstances, including immoderate underlying assumptions, are forward-looking.
All forward-looking statements are based upon the Company's existent expectations and assorted assumptions. The Company believes determination is simply a tenable ground for its expectations and beliefs, but they are inherently uncertain. The Company whitethorn not recognize its expectations, and its beliefs whitethorn not beryllium correct. Actual results could disagree materially from those described oregon implied by specified forward-looking statements arsenic a effect of assorted important factors, including, without limitation, anticipated levels of revenues, aboriginal nationalist oregon determination economical and competitory conditions, and difficulties successful processing the Company's level technology. Consequently, forward-looking statements should beryllium regarded solely arsenic the Company's existent plans, estimates and beliefs. Investors should not spot undue reliance connected forward-looking statements. The Company cannot warrant aboriginal results, events, levels of activity, show oregon achievements. The Company does not undertake and specifically declines immoderate work to update, republish, oregon revise immoderate forward-looking statements to bespeak caller information, aboriginal events oregon circumstances oregon to bespeak the occurrences of unanticipated events, but arsenic whitethorn beryllium required by law.
Investor Contact
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
iTolerance@jtcir.com
Media Contact
Susan Roberts
T: 202.779.0929
sr@roberts-communications.com
SOURCE: iTolerance, Inc.
English (US)